|
(Mark One)
|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2017
|
|
OR
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from to
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
94-3166458
(IRS Employer
Identification No.)
|
|
|
|
Page
|
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
|
March 31,
2017 |
|
December 31,
2016 |
|||||
|
(In thousands, except par value)
|
|||||||
ASSETS
|
||||||||
Current assets:
|
|
|
|
|||||
Cash and cash equivalents
|
$
|
46,348
|
|
|
$
|
54,488
|
|
|
Accounts receivable, net of allowances of $4,416 and $4,796, respectively
|
131,433
|
|
|
150,303
|
|
|||
Inventories
|
76,230
|
|
|
69,297
|
|
|||
Prepaid expenses
|
27,775
|
|
|
28,646
|
|
|||
Other current assets
|
12,593
|
|
|
12,674
|
|
|||
Total current assets
|
294,379
|
|
|
315,408
|
|
|||
Property and equipment, net
|
40,996
|
|
|
42,011
|
|
|||
Long-term investment in sales-type leases, net
|
19,174
|
|
|
20,585
|
|
|||
Goodwill
|
328,216
|
|
|
327,724
|
|
|||
Intangible assets, net
|
184,127
|
|
|
190,283
|
|
|||
Long-term deferred tax assets
|
5,624
|
|
|
4,041
|
|
|||
Other long-term assets
|
37,247
|
|
|
35,051
|
|
|||
Total assets
|
$
|
909,763
|
|
|
$
|
935,103
|
|
|
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
|
|
|
|||||
Accounts payable
|
$
|
38,466
|
|
|
$
|
27,069
|
|
|
Accrued compensation
|
28,677
|
|
|
26,722
|
|
|||
Accrued liabilities
|
31,406
|
|
|
31,195
|
|
|||
Long-term debt, current portion, net
|
8,410
|
|
|
8,410
|
|
|||
Deferred revenue, net
|
90,521
|
|
|
87,516
|
|
|||
Total current liabilities
|
197,480
|
|
|
180,912
|
|
|||
Long-term deferred revenue
|
15,994
|
|
|
17,051
|
|
|||
Long-term deferred tax liabilities
|
42,502
|
|
|
51,592
|
|
|||
Other long-term liabilities
|
8,716
|
|
|
8,210
|
|
|||
Long-term debt, net
|
206,128
|
|
|
245,731
|
|
|||
Total liabilities
|
470,820
|
|
|
503,496
|
|
|||
Commitments and contingencies (Note 10)
|
|
|
|
|
|
|||
Stockholders’ equity:
|
|
|
|
|||||
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued
|
—
|
|
|
—
|
|
|||
Common stock, $0.001 par value, 100,000 shares authorized; 46,272 and 45,778 shares issued; 37,127 and 36,633 shares outstanding, respectively
|
46
|
|
|
46
|
|
|||
Treasury stock at cost, 9,145 shares outstanding
|
(185,074
|
)
|
|
(185,074
|
)
|
|||
Additional paid-in capital
|
541,159
|
|
|
525,758
|
|
|||
Retained earnings
|
91,226
|
|
|
100,396
|
|
|||
Accumulated other comprehensive loss
|
(8,414
|
)
|
|
(9,519
|
)
|
|||
Total stockholders’ equity
|
438,943
|
|
|
431,607
|
|
|||
Total liabilities and stockholders’ equity
|
$
|
909,763
|
|
|
$
|
935,103
|
|
|
Three months ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In thousands, except per share data)
|
||||||
Revenues:
|
|
|
|
||||
Product
|
$
|
98,930
|
|
|
$
|
127,895
|
|
Services and other revenues
|
51,624
|
|
|
43,109
|
|
||
Total revenues
|
150,554
|
|
|
171,004
|
|
||
Cost of revenues:
|
|
|
|
||||
Cost of product revenues
|
63,588
|
|
|
71,918
|
|
||
Cost of services and other revenues
|
22,774
|
|
|
19,141
|
|
||
Total cost of revenues
|
86,362
|
|
|
91,059
|
|
||
Gross profit
|
64,192
|
|
|
79,945
|
|
||
Operating expenses:
|
|
|
|
||||
Research and development
|
16,803
|
|
|
13,838
|
|
||
Selling, general and administrative
|
64,625
|
|
|
64,255
|
|
||
Total operating expenses
|
81,428
|
|
|
78,093
|
|
||
Income (loss) from operations
|
(17,236
|
)
|
|
1,852
|
|
||
Interest and other income (expense), net
|
(2,456
|
)
|
|
(2,171
|
)
|
||
Loss before provision for income taxes
|
(19,692
|
)
|
|
(319
|
)
|
||
Provision for (benefit from) income taxes
|
(8,938
|
)
|
|
59
|
|
||
Net loss
|
$
|
(10,754
|
)
|
|
$
|
(378
|
)
|
Net loss per share:
|
|
|
|
||||
Basic and diluted
|
$
|
(0.29
|
)
|
|
$
|
(0.01
|
)
|
Weighted-average shares outstanding:
|
|
|
|
||||
Basic and diluted
|
36,840
|
|
|
35,740
|
|
|
Three months ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In thousands)
|
||||||
Net loss
|
$
|
(10,754
|
)
|
|
$
|
(378
|
)
|
Other comprehensive income (loss), net of reclassification adjustments:
|
|
|
|
||||
Unrealized gains on interest rate swap contracts
|
182
|
|
|
—
|
|
||
Foreign currency translation adjustments
|
923
|
|
|
(327
|
)
|
||
Other comprehensive income (loss)
|
1,105
|
|
|
(327
|
)
|
||
Comprehensive loss
|
$
|
(9,649
|
)
|
|
$
|
(705
|
)
|
|
Three months ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In thousands)
|
||||||
Operating Activities
|
|
|
|
||||
Net loss
|
$
|
(10,754
|
)
|
|
$
|
(378
|
)
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
|
|
|
||||
Depreciation and amortization
|
12,448
|
|
|
14,473
|
|
||
Loss on disposal of fixed assets
|
—
|
|
|
13
|
|
||
Share-based compensation expense
|
5,511
|
|
|
3,891
|
|
||
Income tax benefits from employee stock plans
|
11
|
|
|
164
|
|
||
Deferred income taxes
|
(9,091
|
)
|
|
(1,042
|
)
|
||
Amortization of debt financing fees
|
397
|
|
|
397
|
|
||
Changes in operating assets and liabilities, net of business acquisitions:
|
|
|
|
||||
Accounts receivable
|
18,870
|
|
|
(1,070
|
)
|
||
Inventories
|
(6,933
|
)
|
|
(5,113
|
)
|
||
Prepaid expenses
|
871
|
|
|
1,983
|
|
||
Other current assets
|
372
|
|
|
324
|
|
||
Investment in sales-type leases
|
1,120
|
|
|
(8,928
|
)
|
||
Other long-term assets
|
(38
|
)
|
|
1,232
|
|
||
Accounts payable
|
11,104
|
|
|
1,568
|
|
||
Accrued compensation
|
1,955
|
|
|
4,114
|
|
||
Accrued liabilities
|
(115
|
)
|
|
417
|
|
||
Deferred revenue
|
1,948
|
|
|
12,663
|
|
||
Other long-term liabilities
|
506
|
|
|
(2,701
|
)
|
||
Net cash provided by operating activities
|
28,182
|
|
|
22,007
|
|
||
Investing Activities
|
|
|
|
||||
Purchases of intangible assets, intellectual property and patents
|
(160
|
)
|
|
(1,074
|
)
|
||
Software development for external use
|
(4,225
|
)
|
|
(3,070
|
)
|
||
Purchases of property and equipment
|
(2,452
|
)
|
|
(4,261
|
)
|
||
Business acquisitions, net of cash acquired
|
—
|
|
|
(271,458
|
)
|
||
Net cash used in investing activities
|
(6,837
|
)
|
|
(279,863
|
)
|
||
Financing Activities
|
|
|
|
||||
Proceeds from debt, net
|
—
|
|
|
247,059
|
|
||
Repayment of debt and revolving credit facility
|
(40,000
|
)
|
|
(20,000
|
)
|
||
Payment for contingent consideration
|
—
|
|
|
(3,000
|
)
|
||
Proceeds from issuances under stock-based compensation plans
|
10,916
|
|
|
5,149
|
|
||
Employees' taxes paid related to restricted stock units
|
(1,052
|
)
|
|
(382
|
)
|
||
Net cash provided by (used in) financing activities
|
(30,136
|
)
|
|
228,826
|
|
||
Effect of exchange rate changes on cash and cash equivalents
|
651
|
|
|
300
|
|
||
Net decrease in cash and cash equivalents
|
(8,140
|
)
|
|
(28,730
|
)
|
||
Cash and cash equivalents at beginning of period
|
54,488
|
|
|
82,217
|
|
||
Cash and cash equivalents at end of period
|
$
|
46,348
|
|
|
$
|
53,487
|
|
|
|
|
|
||||
Supplemental disclosure of non-cash activities
|
|
|
|
||||
Unpaid purchases of property and equipment
|
$
|
865
|
|
|
$
|
468
|
|
Effect of adoption of new accounting standard
|
$
|
1,582
|
|
|
$
|
—
|
|
|
Aesynt
|
|
Ateb
(preliminary) |
|
Total
|
||||||
|
(in thousands)
|
||||||||||
Cash
|
$
|
8,164
|
|
|
$
|
902
|
|
|
$
|
9,066
|
|
Accounts receivable
|
43,312
|
|
|
7,905
|
|
|
51,217
|
|
|||
Inventory
|
19,021
|
|
|
225
|
|
|
19,246
|
|
|||
Other current assets
|
3,787
|
|
|
1,239
|
|
|
5,026
|
|
|||
Total current assets
|
74,284
|
|
|
10,271
|
|
|
84,555
|
|
|||
Property and equipment
|
10,389
|
|
|
2,447
|
|
|
12,836
|
|
|||
Intangibles
|
123,700
|
|
|
12,500
|
|
|
136,200
|
|
|||
Goodwill
|
163,599
|
|
|
20,832
|
|
|
184,431
|
|
|||
Other non-current assets
|
968
|
|
|
1,009
|
|
|
1,977
|
|
|||
Total assets
|
372,940
|
|
|
47,059
|
|
|
419,999
|
|
|||
Current liabilities
|
26,753
|
|
|
2,314
|
|
|
29,067
|
|
|||
Deferred revenue
|
25,512
|
|
|
2,776
|
|
|
28,288
|
|
|||
Non-current deferred tax liabilities
|
38,622
|
|
|
—
|
|
|
38,622
|
|
|||
Other non-current liabilities
|
2,431
|
|
|
367
|
|
|
2,798
|
|
|||
Total liabilities
|
93,318
|
|
|
5,457
|
|
|
98,775
|
|
|||
Total purchase price
|
$
|
279,622
|
|
|
$
|
41,602
|
|
|
$
|
321,224
|
|
Total purchase price, net of cash received
|
$
|
271,458
|
|
|
$
|
40,700
|
|
|
$
|
312,158
|
|
|
Aesynt
|
|
Ateb
|
||||||||
|
Fair value
|
|
Weighted
average useful life |
|
Fair value
|
|
Weighted
average useful life |
||||
|
(In thousands)
|
|
(In years)
|
|
(In thousands)
|
|
(In years)
|
||||
Customer relationships
|
$
|
58,200
|
|
|
14-16
|
|
$
|
8,900
|
|
|
12
|
Developed technology
|
38,800
|
|
|
8
|
|
3,400
|
|
|
5
|
||
Backlog
|
20,200
|
|
|
1-3
|
|
—
|
|
—
|
|||
In-process research and development
(1)
|
3,900
|
|
|
—
|
|
—
|
|
—
|
|||
Non-compete
|
1,800
|
|
|
3
|
|
100
|
|
|
1
|
||
Trade names
|
800
|
|
|
1
|
|
100
|
|
|
1
|
||
Total purchased intangible assets
|
$
|
123,700
|
|
|
|
|
$
|
12,500
|
|
|
|
|
Three months ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In thousands, except per share data)
|
||||||
Net loss
|
$
|
(10,754
|
)
|
|
$
|
(378
|
)
|
Weighted-average shares outstanding — basic
|
36,840
|
|
|
35,740
|
|
||
Effect of dilutive securities from stock award plans
|
—
|
|
|
—
|
|
||
Weighted-average shares outstanding — diluted
|
36,840
|
|
|
35,740
|
|
||
Net loss per share - basic and diluted
|
$
|
(0.29
|
)
|
|
$
|
(0.01
|
)
|
|
|
|
|
||||
Anti-dilutive weighted-average shares related to stock award plans
|
4,236
|
|
|
2,045
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
(In thousands)
|
||||||||||||||
Interest rate swap contracts
|
$
|
—
|
|
|
$
|
1,427
|
|
|
$
|
—
|
|
|
$
|
1,427
|
|
Total financial assets
|
$
|
—
|
|
|
$
|
1,427
|
|
|
$
|
—
|
|
|
$
|
1,427
|
|
Contingent consideration liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,400
|
|
|
$
|
2,400
|
|
Total financial liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,400
|
|
|
$
|
2,400
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
(In thousands)
|
||||||||||||||
Interest rate swap contracts
|
$
|
—
|
|
|
$
|
1,245
|
|
|
$
|
—
|
|
|
$
|
1,245
|
|
Total financial assets
|
$
|
—
|
|
|
$
|
1,245
|
|
|
$
|
—
|
|
|
$
|
1,245
|
|
Contingent consideration liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,400
|
|
|
$
|
2,400
|
|
Total financial liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,400
|
|
|
$
|
2,400
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
|
(In thousands)
|
||||||
Inventories:
|
|
|
|
||||
Raw materials
|
$
|
16,698
|
|
|
$
|
14,322
|
|
Work in process
|
8,114
|
|
|
7,800
|
|
||
Finished goods
|
51,418
|
|
|
47,175
|
|
||
Total inventories
|
$
|
76,230
|
|
|
$
|
69,297
|
|
|
|
|
|
||||
Prepaid expense
|
|
|
|
||||
Prepaid commissions
|
$
|
12,385
|
|
|
$
|
13,176
|
|
Other prepaid expenses
|
15,390
|
|
|
15,470
|
|
||
Total prepaid expense
|
$
|
27,775
|
|
|
$
|
28,646
|
|
|
|
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
Property and equipment:
|
|
|
|
||||
Equipment
|
$
|
66,578
|
|
|
$
|
64,384
|
|
Furniture and fixtures
|
6,614
|
|
|
6,517
|
|
||
Leasehold improvements
|
9,791
|
|
|
9,778
|
|
||
Software
|
35,915
|
|
|
35,607
|
|
||
Construction in progress
|
7,625
|
|
|
7,211
|
|
||
Property and equipment, gross
|
126,523
|
|
|
123,497
|
|
||
Accumulated depreciation and amortization
|
(85,527
|
)
|
|
(81,486
|
)
|
||
Total property and equipment, net
|
$
|
40,996
|
|
|
$
|
42,011
|
|
|
|
|
|
||||
Other long term assets:
|
|
|
|
||||
Capitalized software, net
|
$
|
35,391
|
|
|
$
|
33,233
|
|
Other assets
|
1,856
|
|
|
1,818
|
|
||
Total other long term assets, net
|
$
|
37,247
|
|
|
$
|
35,051
|
|
|
|
|
|
||||
Accrued liabilities:
|
|
|
|
||||
Advance payments from customers
|
$
|
7,971
|
|
|
$
|
7,030
|
|
Rebates and lease buyouts
|
3,905
|
|
|
4,025
|
|
||
Group purchasing organization fees
|
3,549
|
|
|
3,737
|
|
||
Taxes payable
|
3,845
|
|
|
4,003
|
|
||
Other accrued liabilities
|
12,136
|
|
|
12,400
|
|
||
Total accrued liabilities
|
$
|
31,406
|
|
|
$
|
31,195
|
|
|
Foreign currency translation adjustments
|
|
Unrealized gain (loss) on interest rate swap hedges
|
|
Total
|
||||||
|
(In thousands)
|
||||||||||
December 31, 2016
|
$
|
(10,764
|
)
|
|
$
|
1,245
|
|
|
$
|
(9,519
|
)
|
Other comprehensive income (loss) before reclassifications
|
923
|
|
|
176
|
|
|
1,099
|
|
|||
Amounts reclassified from other comprehensive income (loss), net of tax
|
—
|
|
|
6
|
|
|
6
|
|
|||
Net current-period other comprehensive income (loss), net of tax
|
923
|
|
|
182
|
|
|
1,105
|
|
|||
March 31, 2017
|
$
|
(9,841
|
)
|
|
$
|
1,427
|
|
|
$
|
(8,414
|
)
|
|
Foreign currency translation adjustments
|
|
Unrealized gain (loss) on interest rate swap hedges
|
|
Total
|
||||||
|
(In thousands)
|
||||||||||
December 31, 2015
|
$
|
(2,730
|
)
|
|
$
|
—
|
|
|
$
|
(2,730
|
)
|
Other comprehensive income (loss) before reclassifications
|
(327
|
)
|
|
—
|
|
|
(327
|
)
|
|||
Amounts reclassified from other comprehensive income (loss), net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|||
Net current-period other comprehensive income (loss), net of tax
|
(327
|
)
|
|
—
|
|
|
(327
|
)
|
|||
March 31, 2016
|
$
|
(3,057
|
)
|
|
$
|
—
|
|
|
$
|
(3,057
|
)
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
|
(In thousands)
|
||||||
Net minimum lease payments to be received
|
$
|
32,214
|
|
|
$
|
33,591
|
|
Less: Unearned interest income portion
|
(2,506
|
)
|
|
(2,763
|
)
|
||
Net investment in sales-type leases
|
29,708
|
|
|
30,828
|
|
||
Less: Short-term portion
(1)
|
(10,534
|
)
|
|
(10,243
|
)
|
||
Long-term net investment in sales-type leases
|
$
|
19,174
|
|
|
$
|
20,585
|
|
|
March 31,
2017 |
||
|
(In thousands)
|
||
Remaining nine months of 2017
|
$
|
9,397
|
|
2018
|
7,988
|
|
|
2019
|
6,264
|
|
|
2020
|
4,139
|
|
|
2021
|
2,304
|
|
|
Thereafter
|
2,122
|
|
|
Total
|
$
|
32,214
|
|
|
Automation and
Analytics
|
|
Medication
Adherence
|
|
Total
|
||||||
|
(In thousands)
|
||||||||||
Net balance as of December 31, 2016
|
$
|
215,082
|
|
|
$
|
112,642
|
|
|
$
|
327,724
|
|
Foreign currency exchange rate fluctuations
|
342
|
|
|
150
|
|
|
492
|
|
|||
Net balance as of March 31, 2017
|
$
|
215,424
|
|
|
$
|
112,792
|
|
|
$
|
328,216
|
|
|
March 31, 2017
|
||||||||||||||||
|
Gross
carrying
amount
|
|
Accumulated
amortization
|
|
Foreign currency exchange rate fluctuations
|
|
Net
carrying
amount
|
|
Useful life
(years)
|
||||||||
|
(In thousands, except for years)
|
||||||||||||||||
Customer relationships
|
$
|
132,579
|
|
|
$
|
(23,974
|
)
|
|
$
|
143
|
|
|
$
|
108,748
|
|
|
1 - 30
|
Acquired technology
|
73,409
|
|
|
(15,264
|
)
|
|
28
|
|
|
58,173
|
|
|
3 - 20
|
||||
Backlog
|
20,533
|
|
|
(14,875
|
)
|
|
—
|
|
|
5,658
|
|
|
1 - 3
|
||||
Trade names
|
8,607
|
|
|
(4,063
|
)
|
|
5
|
|
|
4,549
|
|
|
1 - 12
|
||||
Patents
|
3,214
|
|
|
(1,273
|
)
|
|
41
|
|
|
1,982
|
|
|
2 - 20
|
||||
Non-compete agreements
|
1,900
|
|
|
(783
|
)
|
|
—
|
|
|
1,117
|
|
|
3
|
||||
In-process technology
|
3,900
|
|
|
—
|
|
|
—
|
|
|
3,900
|
|
|
—
|
||||
Total intangibles assets, net
|
$
|
244,142
|
|
|
$
|
(60,232
|
)
|
|
$
|
217
|
|
|
$
|
184,127
|
|
|
|
|
December 31, 2016
|
||||||||||||||||
|
Gross carrying
amount
|
|
Accumulated
amortization
|
|
Foreign currency exchange rate fluctuations
|
|
Net
carrying
amount
|
|
Useful life
(years)
|
||||||||
|
(In thousands, except for years)
|
||||||||||||||||
Customer relationships
|
$
|
133,358
|
|
|
$
|
(20,930
|
)
|
|
$
|
(596
|
)
|
|
$
|
111,832
|
|
|
1 - 30
|
Acquired technology
|
73,599
|
|
|
(13,287
|
)
|
|
(159
|
)
|
|
60,153
|
|
|
3 - 20
|
||||
Backlog
|
20,550
|
|
|
(14,083
|
)
|
|
—
|
|
|
6,467
|
|
|
1 - 3
|
||||
Trade names
|
8,667
|
|
|
(3,887
|
)
|
|
(31
|
)
|
|
4,749
|
|
|
1 - 12
|
||||
Patents
|
3,154
|
|
|
(1,264
|
)
|
|
—
|
|
|
1,890
|
|
|
2 - 20
|
||||
Non-compete agreements
|
1,900
|
|
|
(608
|
)
|
|
—
|
|
|
1,292
|
|
|
3
|
||||
In-process technology
|
3,900
|
|
|
—
|
|
|
—
|
|
|
3,900
|
|
|
—
|
||||
Total intangibles assets, net
|
$
|
245,128
|
|
|
$
|
(54,059
|
)
|
|
$
|
(786
|
)
|
|
$
|
190,283
|
|
|
|
|
March 31, 2017
|
||
|
(In thousands)
|
||
Remaining nine months of 2017
|
$
|
18,591
|
|
2018
|
22,779
|
|
|
2019
|
17,354
|
|
|
2020
|
16,215
|
|
|
2021
|
14,861
|
|
|
Thereafter (excluding IPR&D)
|
90,427
|
|
|
Total
|
$
|
180,227
|
|
|
December 31, 2016
|
|
Borrowings
|
|
Repayment / Amortization
|
|
March 31, 2017
|
||||||||
|
(In thousands)
|
||||||||||||||
Term loan facility
|
$
|
192,500
|
|
|
$
|
—
|
|
|
$
|
(2,500
|
)
|
|
$
|
190,000
|
|
Revolving credit facility
|
68,000
|
|
|
—
|
|
|
(37,500
|
)
|
|
30,500
|
|
||||
Total debt under the facilities
|
260,500
|
|
|
—
|
|
|
(40,000
|
)
|
|
220,500
|
|
||||
Less: Deferred issuance cost
|
(6,359
|
)
|
|
—
|
|
|
397
|
|
|
(5,962
|
)
|
||||
Total Debt, net of deferred issuance cost
|
$
|
254,141
|
|
|
$
|
—
|
|
|
$
|
(39,603
|
)
|
|
$
|
214,538
|
|
Long term debt, current portion, net of deferred issuance cost
|
8,410
|
|
|
|
|
|
|
8,410
|
|
||||||
Long term debt, net of deferred issuance cost
|
$
|
245,731
|
|
|
|
|
|
|
$
|
206,128
|
|
|
Three months ended
|
||||||
|
March 31, 2017
|
|
March 31, 2016
|
||||
|
(In thousands)
|
||||||
Cost of product and service revenues
|
$
|
982
|
|
|
$
|
549
|
|
Research and development
|
897
|
|
|
641
|
|
||
Selling, general and administrative
|
3,632
|
|
|
2,701
|
|
||
Total share-based compensation expense
|
$
|
5,511
|
|
|
$
|
3,891
|
|
|
Three months ended
|
||||
|
March 31, 2017
|
|
March 31, 2016
|
||
Stock Option Plans
|
|
|
|
||
Expected life, years
|
4.67
|
|
|
4.92
|
|
Expected volatility, %
|
31.1
|
%
|
|
32.6
|
%
|
Risk free interest rate, %
|
1.89
|
%
|
|
1.40
|
%
|
Estimated forfeiture rate %
|
7.7
|
%
|
|
8.6
|
%
|
Dividend yield, %
|
—
|
%
|
|
—
|
%
|
|
Three months ended
|
||||
|
March 31, 2017
|
|
March 31, 2016
|
||
Employee Stock Purchase Plan
|
|
|
|
||
Expected life, years
|
0.5-2.0
|
|
|
0.5-2.0
|
|
Expected volatility, %
|
25.8-32.8%
|
|
|
25.8-34.8%
|
|
Risk free interest rate, %
|
0.52-1.31%
|
|
|
0.26-0.79%
|
|
Dividend yield, %
|
—
|
%
|
|
—
|
%
|
|
Number of
Shares
|
|
Weighted-Average
Exercise Price
|
|
Weighted-Average
Remaining Years
|
|
Aggregate
Intrinsic Value
|
|||||
|
(In thousands, except per share data)
|
|||||||||||
Stock Options
|
|
|
|
|
|
|
|
|||||
Outstanding at December 31, 2016
|
3,214
|
|
|
$
|
26.06
|
|
|
7.3
|
|
$
|
26,331
|
|
Granted
|
363
|
|
|
36.67
|
|
|
|
|
|
|||
Exercised
|
(188
|
)
|
|
22.86
|
|
|
|
|
|
|||
Expired
|
(1
|
)
|
|
32.59
|
|
|
|
|
|
|||
Forfeited
|
(38
|
)
|
|
31.72
|
|
|
|
|
|
|||
Outstanding at March 31, 2017
|
3,350
|
|
|
$
|
27.33
|
|
|
7.4
|
|
$
|
44,631
|
|
Exercisable at March 31, 2017
|
1,493
|
|
|
$
|
20.88
|
|
|
5.5
|
|
$
|
29,519
|
|
Vested and expected to vest at March 31, 2017 and thereafter
|
3,168
|
|
|
$
|
26.96
|
|
|
7.3
|
|
$
|
43,388
|
|
|
Number of
Shares
|
|
Weighted-Average
Grant Date Fair Value
|
|
Weighted-Average
Remaining Years
|
|
Aggregate
Intrinsic Value
|
|||||
|
(In thousands, except per share data)
|
|||||||||||
Restricted Stock Units ("RSUs")
|
|
|
|
|
|
|
|
|||||
Outstanding at December 31, 2016
|
505
|
|
|
$
|
31.42
|
|
|
1.6
|
|
$
|
17,135
|
|
Granted
|
74
|
|
|
36.57
|
|
|
|
|
|
|||
Vested
|
(43
|
)
|
|
28.12
|
|
|
|
|
|
|||
Forfeited
|
(9
|
)
|
|
31.97
|
|
|
|
|
|
|||
Outstanding and unvested at March 31, 2017
|
527
|
|
|
$
|
32.39
|
|
|
1.5
|
|
$
|
21,418
|
|
|
Number of
Shares
|
|
Weighted-Average
Grant Date Fair Value
|
|||
|
(In thousands, except per share data)
|
|||||
Restricted Stock Awards ("RSAs")
|
|
|
|
|||
Outstanding at December 31, 2016
|
30
|
|
|
$
|
31.57
|
|
Granted
|
—
|
|
|
|
|
|
Vested
|
—
|
|
|
|
|
|
Forfeited
|
—
|
|
|
|
|
|
Outstanding and unvested at March 31, 2017
|
30
|
|
|
$
|
31.57
|
|
|
Number of
Shares
|
|
Weighted-Average
Grant Date Fair Value Per Unit
|
|||
|
(In thousands, except per share data)
|
|||||
Performance-based Restricted Stock Units ("PSUs")
|
|
|
|
|||
Outstanding at December 31, 2016
|
184
|
|
|
$
|
24.89
|
|
Granted
|
126
|
|
|
32.37
|
|
|
Vested
|
(31
|
)
|
|
24.66
|
|
|
Forfeited
|
—
|
|
|
—
|
|
|
Outstanding and unvested at March 31, 2017
|
279
|
|
|
$
|
28.29
|
|
|
Number of Shares
|
|
|
(In thousands)
|
|
Share options outstanding
|
3,350
|
|
Non-vested restricted share awards
|
836
|
|
Shares authorized for future issuance
|
2,411
|
|
ESPP shares available for future issuance
|
2,572
|
|
Total shares reserved for future issuance
|
9,169
|
|
|
Three months ended
|
||||||||||||||||||||||
|
March 31, 2017
|
|
March 31, 2016
|
||||||||||||||||||||
|
Automation and
Analytics
|
|
Medication
Adherence
|
|
Total
|
|
Automation and
Analytics
|
|
Medication
Adherence
|
|
Total
|
||||||||||||
|
(In thousands)
|
||||||||||||||||||||||
Revenues
|
$
|
124,171
|
|
|
$
|
26,383
|
|
|
$
|
150,554
|
|
|
$
|
148,945
|
|
|
$
|
22,059
|
|
|
$
|
171,004
|
|
Cost of revenues
|
68,761
|
|
|
17,601
|
|
|
86,362
|
|
|
77,207
|
|
|
13,852
|
|
|
91,059
|
|
||||||
Gross profit
|
55,410
|
|
|
8,782
|
|
|
64,192
|
|
|
71,738
|
|
|
8,207
|
|
|
79,945
|
|
||||||
Operating expenses
|
50,747
|
|
|
11,196
|
|
|
61,943
|
|
|
52,205
|
|
|
5,611
|
|
|
57,816
|
|
||||||
Income (loss) from segment operations
|
$
|
4,663
|
|
|
$
|
(2,414
|
)
|
|
$
|
2,249
|
|
|
$
|
19,533
|
|
|
$
|
2,596
|
|
|
$
|
22,129
|
|
Corporate costs
|
|
|
|
|
19,485
|
|
|
|
|
|
|
20,277
|
|
||||||||||
Income (loss) from operations
|
|
|
|
|
$
|
(17,236
|
)
|
|
|
|
|
|
$
|
1,852
|
|
|
Three months ended
|
||||||
|
March 31,
2017 |
|
March 31,
2016 |
||||
|
(In thousands)
|
||||||
United States
|
$
|
132,280
|
|
|
$
|
143,493
|
|
Rest of world
(1)
|
18,274
|
|
|
27,511
|
|
||
Total revenues
|
$
|
150,554
|
|
|
$
|
171,004
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
|
(In thousands)
|
||||||
United States
|
$
|
35,471
|
|
|
$
|
36,497
|
|
Rest of world
(1)
|
5,525
|
|
|
5,514
|
|
||
Total property and equipment, net
|
$
|
40,996
|
|
|
$
|
42,011
|
|
|
Automation and Analytics
|
|
Medication Adherence
|
|
Corporate
|
|
Total
|
||||||||
|
(in thousands)
|
||||||||||||||
Cost of revenue
|
$
|
1,266
|
|
|
$
|
431
|
|
|
$
|
—
|
|
|
$
|
1,697
|
|
Research and development
|
1,006
|
|
|
62
|
|
|
—
|
|
|
1,068
|
|
||||
Selling, general and administrative
|
480
|
|
|
103
|
|
|
417
|
|
|
1,000
|
|
||||
Total
|
$
|
2,752
|
|
|
$
|
596
|
|
|
$
|
417
|
|
|
$
|
3,765
|
|
•
|
our expectations regarding our future product bookings;
|
•
|
our ability to acquire companies, businesses, products or technologies on commercially reasonable terms and integrate such acquisitions effectively;
|
•
|
the extent and timing of future revenues, including the amounts of our current backlog, which represents firm orders that have not completed installation and therefore have not been recognized as revenue;
|
•
|
the size or growth of our market or market share;
|
•
|
the opportunity presented by new products, emerging markets and international markets;
|
•
|
our ability to align our cost structure and headcount with our current business expectations;
|
•
|
the operating margins or earnings per share goals we may set;
|
•
|
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and
|
•
|
our ability to generate cash from operations and our estimates regarding the sufficiency of our cash resources;
|
•
|
Development of differentiated solutions.
We invest in the development of products that we believe bring patient safety and workflow efficiency to our customers’ operations that they cannot get from other competing solutions. These differentiators may be as small as how a transaction operates or information provided on a report or as large as the entire automation of a workflow that would otherwise be completed manually. We intend to continue our
|
•
|
Deliver our solutions to new markets
.
Areas of healthcare where work is done manually may benefit from our existing solutions. These areas include hospitals that continue to employ manual operations, healthcare segments of the U.S. market outside hospitals and markets outside the United States. We weigh the cost of entering these new markets against the expected benefits and focus on the markets that we believe are most likely to adopt our products.
|
•
|
Expansion of our solutions through acquisitions and partnerships.
Our acquisitions have generally been focused on automation of manual workflows or data analytics, which is the enhancement of data for our customers’ decision-making processes. We believe that expansion of our product lines through acquisition and partnerships to meet our customers changing and evolving expectations is a key component to our historical and future success.
|
•
|
Our expectation that the overall market demand for healthcare services will increase as the population grows, life expectancies continue to increase and the quality and availability of healthcare services increases;
|
•
|
Our expectation that the environment of increased patient safety awareness, increased regulatory control, increased demand for innovative products that improve the care experience and increased need for workflow efficiency through the adoption of technology in the healthcare industry will make our solutions a priority in the capital budgets of healthcare facilities; and
|
•
|
Our belief that healthcare customers will continue to value a consultative customer experience from their suppliers.
|
•
|
Revenue recognition;
|
•
|
Accounts receivable and notes receivable (net investment in sales-type leases);
|
•
|
Inventory valuation;
|
•
|
Capitalized software development cost;
|
•
|
Valuation and impairment of goodwill, intangible assets and other long-lived assets;
|
•
|
Business combinations;
|
•
|
Valuation of share-based awards; and
|
•
|
Accounting for income taxes.
|
|
Three months ended March 31,
|
|||||||||||||
|
|
|
|
|
Change in
|
|||||||||
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||
|
(Dollars in thousands)
|
|||||||||||||
Product revenues
|
$
|
98,930
|
|
|
$
|
127,895
|
|
|
$
|
(28,965
|
)
|
|
(23
|
)%
|
Percentage of total revenues
|
66
|
%
|
|
75
|
%
|
|
|
|
|
|||||
Service and other revenues
|
51,624
|
|
|
43,109
|
|
|
8,515
|
|
|
20
|
%
|
|||
Percentage of total revenues
|
34
|
%
|
|
25
|
%
|
|
|
|
|
|||||
Total revenues
|
$
|
150,554
|
|
|
$
|
171,004
|
|
|
$
|
(20,450
|
)
|
|
(12
|
)%
|
|
Three months ended March 31,
|
|||||||||||||
|
|
|
|
|
Change in
|
|||||||||
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||
Revenues:
|
(Dollars in thousands)
|
|||||||||||||
Automation and Analytics
|
$
|
124,171
|
|
|
$
|
148,945
|
|
|
$
|
(24,774
|
)
|
|
(17
|
)%
|
Percentage of total revenues
|
82
|
%
|
|
87
|
%
|
|
|
|
|
|||||
Medication Adherence
|
26,383
|
|
|
22,059
|
|
|
4,324
|
|
|
20
|
%
|
|||
Percentage of total revenues
|
18
|
%
|
|
13
|
%
|
|
|
|
|
|||||
Total revenues
|
$
|
150,554
|
|
|
$
|
171,004
|
|
|
$
|
(20,450
|
)
|
|
(12
|
)%
|
|
Three months ended March 31,
|
|||||||||||||
|
|
|
|
|
Change in
|
|||||||||
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||
Cost of revenues:
|
(Dollars in thousands)
|
|||||||||||||
Automation and Analytics
|
$
|
68,761
|
|
|
$
|
77,207
|
|
|
$
|
(8,446
|
)
|
|
(11
|
)%
|
As a percentage of related revenues
|
55
|
%
|
|
52
|
%
|
|
|
|
|
|||||
Medication Adherence
|
17,601
|
|
|
13,852
|
|
|
3,749
|
|
|
27
|
%
|
|||
As a percentage of related revenues
|
67
|
%
|
|
63
|
%
|
|
|
|
|
|||||
Total cost of revenues
|
$
|
86,362
|
|
|
$
|
91,059
|
|
|
$
|
(4,697
|
)
|
|
(5
|
)%
|
As a percentage of total revenues
|
57
|
%
|
|
53
|
%
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|||||||
Gross profit:
|
|
|
|
|
|
|
|
|||||||
Automation and Analytics
|
$
|
55,410
|
|
|
$
|
71,738
|
|
|
$
|
(16,328
|
)
|
|
(23
|
)%
|
Automation and Analytics gross margin
|
45
|
%
|
|
48
|
%
|
|
|
|
|
|||||
Medication Adherence
|
8,782
|
|
|
8,207
|
|
|
575
|
|
|
7
|
%
|
|||
Medication Adherence gross margin
|
33
|
%
|
|
37
|
%
|
|
|
|
|
|||||
Total gross profit
|
$
|
64,192
|
|
|
$
|
79,945
|
|
|
$
|
(15,753
|
)
|
|
(20
|
)%
|
Total gross margin
|
43
|
%
|
|
51
|
%
|
|
|
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
|
(In thousands)
|
||||||
Cash and cash equivalents
|
$
|
46,348
|
|
|
$
|
54,488
|
|
|
|
|
|
||||
Working Capital
|
$
|
96,899
|
|
|
$
|
134,496
|
|
|
Three months ended
|
||||||
|
March 31,
2017 |
|
March 31,
2016 |
||||
|
(In thousands)
|
||||||
Net cash provided by (used in):
|
|
|
|
||||
Operating activities
|
$
|
28,182
|
|
|
$
|
22,007
|
|
Investing activities
|
(6,837
|
)
|
|
(279,863
|
)
|
||
Financing activities
|
(30,136
|
)
|
|
228,826
|
|
||
Effect of exchange rate changes on cash and cash equivalents
|
651
|
|
|
300
|
|
||
Net decrease in cash and cash equivalents
|
$
|
(8,140
|
)
|
|
$
|
(28,730
|
)
|
|
Payments due by period
|
||||||||||||||||||
|
Total
|
|
Remainder of 2017
|
|
2018 and 2019
|
|
2020 and 2021
|
|
Thereafter
|
||||||||||
|
(In thousands)
|
||||||||||||||||||
Operating leases
(1)
|
$
|
55,654
|
|
|
$
|
8,522
|
|
|
$
|
22,707
|
|
|
$
|
14,083
|
|
|
$
|
10,342
|
|
Purchase obligations
(2)
|
55,642
|
|
|
53,935
|
|
|
656
|
|
|
753
|
|
|
298
|
|
|||||
Term loan facility
(3)
|
190,000
|
|
|
7,500
|
|
|
37,500
|
|
|
145,000
|
|
|
—
|
|
|||||
Revolving credit facility
(3)
|
30,500
|
|
|
—
|
|
|
—
|
|
|
30,500
|
|
|
—
|
|
|||||
Total
(4)
|
$
|
331,796
|
|
|
$
|
69,957
|
|
|
$
|
60,863
|
|
|
$
|
190,336
|
|
|
$
|
10,640
|
|
(1)
|
Commitments under operating leases relate primarily to leasehold property and office equipment.
|
(2)
|
We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. These amounts are associated with agreements that are enforceable and legally binding. The amounts under such contracts are included in the table above because we believe that cancellation of these contracts is unlikely and we expect to make future cash payments according to the contract terms or in similar amounts for similar materials.
|
(3)
|
Amounts shown for Term loan and revolving credit facility are principal repayments only. Due to use of interest rate swaps, the cash interest expense is partly variable and partly fixed, and is not reflected in the above table. Refer to Note 8, Debt, of the Notes to the Condensed Consolidated Financial Statements included in this quarterly report.
|
(4)
|
We have recorded $6.9 million for uncertain tax positions under long-term liabilities as of
March 31, 2017
in accordance with U.S. GAAP. As these liabilities do not reflect actual tax assessments, the timing and amount of payments we might be required to make will depend upon a number of factors. Accordingly, as the timing and amount of payment cannot be estimated, the $6.9 million in uncertain tax position liabilities have not been included in the table above.
|
•
|
difficulties in combining previously separate businesses into a single unit and the complexity of managing a more dispersed organization as sites are acquired;
|
•
|
complying with international labor laws that may restrict our ability to right-size organizations and gain synergies across acquired operations;
|
•
|
complying with regulatory requirements, such as those of the Food and Drug Administration, that we were not previously subject to;
|
•
|
the substantial costs that may be incurred and the substantial diversion of management's attention from day-to-day business when evaluating and negotiating such transactions and then integrating an acquired business;
|
•
|
discovery, after completion of the acquisition, of liabilities assumed from the acquired business or of assets acquired that are broader in scope and magnitude or are more difficult to manage than originally assumed;
|
•
|
failure to achieve anticipated benefits such as cost savings and revenue enhancements;
|
•
|
difficulties related to assimilating the products or key personnel of an acquired business;
|
•
|
failure to understand and compete effectively in markets in which we have limited previous experience; and
|
•
|
difficulties in integrating newly acquired products and solutions into a logical offering that our customers understand and embrace.
|
•
|
inability or failure to expand bookings and sales;
|
•
|
inability to maintain business relationships with customers and suppliers of newly acquired companies, such as Ateb and InPharmics, due to post-acquisition disruption;
|
•
|
inability or failure to effectively coordinate sales and marketing efforts to communicate the capabilities of the combined company;
|
•
|
inability or failure to successfully integrate and harmonize financial reporting and information technology systems;
|
•
|
inability or failure to achieve the expected operational and cost efficiencies; and
|
•
|
loss of key employees.
|
•
|
limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;
|
•
|
limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;
|
•
|
require us to use a substantial portion of our cash flow from operations to make debt service payments;
|
•
|
limit our flexibility to plan for, or react to, changes in our business and industry;
|
•
|
place us at a competitive disadvantage compared to our less leveraged competitors; and
|
•
|
increase our vulnerability to the impact of adverse economic and industry conditions.
|
•
|
certain competitors may offer or have the ability to offer a broader range of solutions in the marketplace that we are unable to match;
|
•
|
certain competitors may develop alternative solutions to the customer problems our products are designed to solve that may provide a better customer outcome or a lower cost of operation;
|
•
|
certain competitors may develop new features or capabilities for their products not previously offered that could compete directly with our products;
|
•
|
competitive pressures could result in increased price competition for our products and services, fewer customer orders and reduced gross margins, any of which could harm our business;
|
•
|
current and potential competitors may make strategic acquisitions or establish cooperative relationships among themselves or with third parties, including larger, more established healthcare supply companies, such as the acquisition of CareFusion Corporation by Becton Dickenson Corporation, thereby increasing their ability to develop and offer a broader suite of products and services to address the needs of our prospective customers;
|
•
|
our competitive environment is currently experiencing a significant degree of consolidation which could lead to competitors developing new business models that require us to adapt how we market, sell or distribute our products;
|
•
|
other established or emerging companies may enter the medication management and supply chain solutions market with products and services that are preferred by our current and potential customers based on factors such as features, capabilities or cost;
|
•
|
our competitors may develop, license or incorporate new or emerging technologies or devote greater resources to the development, promotion and sale of their products and services than we do;
|
•
|
certain competitors have greater brand name recognition and a more extensive installed base of medication and supply dispensing systems or other products and services than we do, and such advantages could be used to increase their market share;
|
•
|
certain competitors may have existing business relationships with our current and potential customers, which may cause these customers to purchase medication and supply dispensing systems or automation solutions from these competitors; and
|
•
|
our competitors may secure products and services from suppliers on more favorable terms or secure exclusive arrangements with suppliers or buyers that may impede the sales of our products and services.
|
•
|
our reliance on distributors for the sale and post-sale support of our automated dispensing systems outside the United States and Canada;
|
•
|
the difficulty of managing an organization operating in various countries;
|
•
|
political sentiment against international outsourcing of production;
|
•
|
reduced protection for intellectual property rights, particularly in jurisdictions that have less developed intellectual property regimes;
|
•
|
changes in foreign regulatory requirements;
|
•
|
the requirement to comply with a variety of international laws and regulations, including privacy, labor, import, export, environmental standards, tax, anti-bribery and employment laws and changes in tariff rates;
|
•
|
fluctuations in currency exchange rates and difficulties in repatriating funds from certain countries;
|
•
|
additional investment, coordination and lead-time necessary to successfully interface our automation solutions with the existing information systems of our customers or potential customers outside of the United States; and
|
•
|
political unrest, terrorism and the potential for other hostilities in areas in which we have facilities.
|
•
|
incur or assume liens or additional debt or provide guarantees in respect of obligations or other persons;
|
•
|
issue redeemable preferred stock;
|
•
|
pay dividends or distributions or redeem or repurchase capital stock;
|
•
|
prepay, redeem or repurchase certain debt;
|
•
|
make loans, investments, acquisitions (including acquisitions of exclusive licenses) and capital expenditures;
|
•
|
enter into agreements that restrict distributions from our subsidiaries;
|
•
|
sell assets and capital stock of our subsidiaries;
|
•
|
enter into certain transactions with affiliates; and
|
•
|
consolidate or merge with or into, or sell substantially all of our assets to, another person.
|
•
|
our ability to successfully install our products on a timely basis and meet other contractual obligations necessary to recognize revenue;
|
•
|
our ability to execute the manufacturing ramp up of our new XT Series;
|
•
|
the impact of the reduction in our workforce and closure of our Nashville, Tennessee and Slovenia facilities;
|
•
|
our ability to continue cost reduction efforts;
|
•
|
our ability to implement development and manufacturing Centers of Excellence;
|
•
|
the size, product mix and timing of orders for our medication and supply dispensing systems, and our medication packaging systems, and their installation and integration;
|
•
|
the overall demand for healthcare medication management and supply chain solutions;
|
•
|
changes in pricing policies by us or our competitors;
|
•
|
the number, timing and significance of product enhancements and new product announcements by us or our competitors;
|
•
|
the timing and significance of any acquisition or business development transactions that we may consider or negotiate and the revenues, costs and earnings that may be associated with these transactions;
|
•
|
the relative proportions of revenues we derive from products and services;
|
•
|
fluctuations in the percentage of sales attributable to our international business;
|
•
|
our customers' budget cycles;
|
•
|
changes in our operating expenses and our ability to stabilize expenses;
|
•
|
expenses incurred to remediate product quality or safety issues;
|
•
|
our ability to generate cash from our accounts receivable on a timely basis;
|
•
|
the performance of our products;
|
•
|
changes in our business strategy;
|
•
|
macroeconomic and political conditions, including fluctuations in interest rates, tax increases and availability of credit markets; and
|
•
|
volatility in our stock price and its effect on equity-based compensation expense.
|
•
|
changes in our operating results;
|
•
|
developments in our relationships with corporate customers;
|
•
|
developments with respect to the Aesynt and Ateb Acquisitions;
|
•
|
changes in the ratings of our common stock by securities analysts;
|
•
|
announcements by us or our competitors of technological innovations or new products;
|
•
|
announcements by us or our competitors of acquisitions of businesses, products or technologies; or
|
•
|
general economic and market conditions.
|
|
|
OMNICELL, INC.
|
||
Date:
|
May 5, 2017
|
By:
|
|
/s/ Peter J. Kuipers
|
|
|
|
|
Peter J. Kuipers,
Executive Vice President & Chief Financial Officer |
|
|
|
|
Incorporated By Reference
|
||||||
Exhibit Number
|
|
Exhibit Description
|
|
Form
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
|
|
|
|
|
|
|
|
|
|
|
2.1
|
|
Securities Purchase Agreement, dated October 29, 2015, among Omnicell, Inc., Aesynt Holding, L.P., Aesynt, Ltd. and Aesynt Coöperatief U.A.
|
|
8-K
|
|
000-33043
|
|
2.1
|
|
10/29/2015
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
|
S-1
|
|
333-57024
|
|
3.1
|
|
3/14/2001
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Omnicell, Inc.
|
|
10-Q
|
|
000-33043
|
|
3.2
|
|
8/9/2010
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
Certificate of Designation of Series A Junior Participating Preferred Stock
|
|
10-K
|
|
000-33043
|
|
3.2
|
|
3/28/2003
|
|
|
|
|
|
|
|
|
|
|
|
3.4
|
|
Bylaws of Omnicell, Inc., as amended
|
|
10-Q
|
|
000-33043
|
|
3.3
|
|
8/9/2007
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Reference is made to Exhibits 3.1, 3.2, 3.3 and 3.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Form of Common Stock Certificate
|
|
S-1
|
|
333-57024
|
|
4.1
|
|
3/14/2001
|
|
|
|
|
|
|
|
|
|
|
|
10.1
+ *
|
|
Amended and restated severance benefit plan, effective March 7, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2
+
|
|
First Amendment to Credit Agreement and Collateral Agreement, dated as of April 11, 2017, by and among Omnicell, Inc., each subsidiary guarantor; each lender party thereto; and Wells Fargo Bank, National Association, as administrative agent.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3+
|
|
Fifth Amendment to Lease, dated April 28, 2017 between McKnight Cranberry III, L.P., a Delaware limited Partnership and Aesynt Incorporated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1
+
|
|
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2
+
|
|
Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1
+
|
|
Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS
+
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH
+
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL
+
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF
+
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB
+
|
|
XBRL Taxonomy Extension Labels Linkbase Document
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE
+
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
+
|
Filed herewith.
|
*
|
Indicates management contract or compensatory plan.
|
(1)
|
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
|
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
|
|
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
|
EMPLOYEE
|
||||
|
|
||||
|
|
||||
|
Signature:
|
|
|
||
|
|
|
|||
|
Print Name:
|
|
|
||
|
|
|
|||
|
|
|
|||
|
Date:
|
|
|
|
EMPLOYEE
|
||||
|
|
||||
|
|
||||
|
Signature:
|
|
|
||
|
|
|
|||
|
Print Name:
|
|
|
||
|
|
|
|||
|
|
|
|||
|
Date:
|
|
|
||
|
|
|
|
|
|
EMPLOYEE
|
||
|
|
||
|
|
||
|
Signature:
|
|
|
|
|
||
|
Print Name:
|
|
|
|
|
||
|
|
||
|
Date:
|
|
|
|
|
|
|
|
Appendix A Adopted: March 7, 2017
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
||
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
1
|
|
1 month
|
2
|
|
2 months
|
3
|
|
3 months
|
For each 5 Years of Service
|
|
1 extra month
|
|
Appendix B Adopted: March 7, 2017
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
||
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
4 months
|
For each 5 Years of Service
|
|
1 extra month
|
|
Appendix B Adopted: March 7, 2017
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
||
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
6 months
|
For each 5 Years of Service
|
|
2 extra months
|
|
Appendix B Adopted: March 7, 2017
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
||
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
Years of Service
|
|
Months of Base Salary
|
Not relevant
|
|
12 months
|
For each 5 Years of Service
|
|
2 extra months
|
|
Appendix B Adopted: March 7, 2017
|
||
|
|
||
|
OMNICELL, INC.
|
||
|
|
||
|
|
||
|
By:
|
/s/ Dan S. Johnston
|
|
|
|
||
|
Title:
|
EVP and Chief Legal & Administrative Officer
|
|
|
|
|
|
1.
|
Recitals.
The foregoing recitals are incorporated herein by reference and made a part of this Fifth Amendment as though fully set forth herein. All capitalized terms used but not otherwise defined or re-defined in this Fifth Amendment shall have the meaning ascribed to them in the Lease. For purposes of this Fifth Amendment, (i) the term “
Fifth Amendment Effective Date
” shall mean the date on which this Fifth Amendment is fully executed and delivered by and between Landlord and Tenant, (ii) the term “
Fifth Amendment Commencement Date
” shall mean the date that is one hundred fifty (150) days following the Fifth Amendment Effective Date, (iii) the term “
Fifth Amendment Rent Commencement Date
” shall mean the date that is one
|
2.
|
Premises
. Effective on and after the Fifth Amendment Effective Date, the term “
Premises
” when referred to in this Fifth Amendment and in the Lease shall mean
116,258
rentable square feet consisting of (i) the Existing Premises containing 102,741 rentable square feet on a portion of the 1
st
floor and the entire 2
nd
, 3
rd
, and 4
th
floors of the Building, and (ii) the Fifth Amendment Expansion Premises containing 13,517 rentable square feet on the 1
st
floor of the Building.
|
3.
|
Lease Term.
Notwithstanding anything to the contrary contained in the Lease, the Lease Term is hereby extended for a period of 108 full calendar months beginning on January 1, 2020 (“
Third Extended Term
”) so that the Lease Term shall expire on December 31, 2028 (“
Expiration Date
”), subject to Tenant’s Renewal Option as set forth in Paragraph 9 of this Fifth Amendment.
|
4.
|
Base Rent.
Prior to the Fifth Amendment Rent Commencement Date, Tenant shall continue to pay Base Rent in the amount of $216,184.19 as set forth in the Lease (see paragraph 4 of the Fourth Amendment). Notwithstanding anything to the contrary contained in the Lease, on and after the Fifth Amendment Rent Commencement Date, Tenant shall pay to Landlord Base Rent for the Premises in monthly installments on the first day of each calendar month, in advance, without offset or deduction of any kind, as follows:
|
5.
|
Tenant’s Share.
Prior to the Fifth Amendment Commencement Date, Tenant’s Share shall remain at 86.02% (see paragraph 5 of the Fourth Amendment). Notwithstanding anything to the contrary contained in the Lease, Landlord and Tenant acknowledge and agree that, beginning on the Fifth Amendment Commencement Date and ending on the Expiration Date, Tenant’s Share shall be 97.33% (116,258 / 119,444), as may be adjusted from time to time in accordance with Section 1.2 of the Original Lease.
|
6.
|
Operating Cost Base Year, Janitorial, HVAC Charge.
|
7.
|
Real Estate Tax Base Year.
Prior to January 1, 2020, Tenant’s Real Estate Tax Base Year shall remain Calendar Year 2017. Notwithstanding anything to the contrary contained in the Lease, Landlord and Tenant acknowledge and agree that beginning on January 1, 2020 and ending on the Expiration Date, the Real Estate Tax Base Year shall be Calendar Year 2020.
|
8.
|
Condition of Premises, Tenant Improvement Allowance.
Tenant has inspected the Fifth Amendment Expansion Premises, is familiar with the condition of the Fifth Amendment Expansion Premises and accepts the Fifth Amendment Expansion Premises and the Existing Premises in current “as-is” condition, with all faults and without any work or improvement required of Landlord. Landlord shall deliver possession of the Fifth Amendment Expansion Premises to Tenant on the Fifth Amendment Effective Date. Notwithstanding anything to the contrary set forth in the Lease, Landlord shall not be responsible for performing any demolition, or any work or improvements to or at the Fifth Amendment Expansion Premises or the Existing Premises.
|
“50.
|
RENEWAL OPTION
|
10.
|
Expansion.
Article 52 of the Lease, as amended by Paragraph 12 of the First Amendment, Paragraph 13 of the Third Amendment and Paragraph 10 of the Fourth Amendment, shall be deleted in its entirety and in lieu thereof shall be inserted the following:
|
11.
|
Tenant’s Early Termination Right.
Paragraph 12 of the Fourth Amendment is hereby deleted in its entirety and rendered null and void reflecting the intent of Landlord and Tenant that Tenant’s right to exercise the Termination Option set forth therein is without further force or effect.
|
12.
|
Tenant’s Address.
Notwithstanding anything to the contrary contained in the Lease, the Notice address for Tenant shall be as follows, until written notice of a change in address is issued to Tenant:
|
13.
|
Brokers.
Tenant was represented in the transaction evidenced by this Fifth Amendment by Colliers International/Pittsburgh (Patrick Sentner), a licensed real estate broker (“
Tenant’s Broker”).
Landlord also was represented in the transaction evidenced by this Fifth Amendment by CBRE (Ralston Merchant) (“
Landlord’s Broker
”). Landlord shall be solely responsible for paying the commission or fee owed to the Tenant’s Broker and the Landlord’s Broker in accordance with a mutually acceptable separate commission agreement. Each party to this Fifth Amendment shall indemnify, defend and hold harmless the other party from and against any and all claims asserted against such other indemnified party by any other real estate broker, finder or intermediary claiming representation of the indemnifying party (excluding, with
|
14.
|
Effect.
All other terms, conditions, covenants, agreements and provisions contained in the Lease that are not revised by or in conflict with the terms of this Fifth Amendment shall remain in full force and effect and are hereby ratified and confirmed by Landlord and Tenant to the extent consistent with this Fifth Amendment.
|
15.
|
No Offer.
The submission of this Fifth Amendment to Tenant or its broker or other agent does not constitute an offer. This Fifth Amendment shall have no force or effect until: (a) it is executed and delivered by Tenant to Landlord; and (b) it is executed and delivered by Landlord to Tenant.
|
By:
|
McKnight Cranberry III GP, LLC, General Partner
|
ATTEST
|
AESYNT INCORPORATED, a Pennsylvania corporation
|
|
|
May 5, 2017
|
/s/ Randall A. Lipps
|
|
Randall A. Lipps
|
|
President and Chief Executive Officer
|
|
|
May 5, 2017
|
/s/ Peter J. Kuipers
|
|
Peter J. Kuipers
|
|
Executive Vice President & Chief Financial Officer
|
/s/ Randall A. Lipps
|
|
/s/ Peter J. Kuipers
|
Randall A. Lipps
|
|
Peter J. Kuipers
|
President and Chief Executive Officer
|
|
Executive Vice President & Chief Financial Officer
|